Compare Abeona Therapeutics Inc (ABEO) vs MPLX LP (MPLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs MPLX LP — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while MPLX LP trades at $57 (market cap $58.36B). The key difference: MPLX LP is far larger — about 156.3× Abeona Therapeutics Inc's market cap, and MPLX LP pays a 7.49% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MPLX | |
|---|---|---|
Market Cap | $373.32M | $58.36B |
Sector | Health | Technology |
52-Week High | $7.23 | $59.17 |
52-Week Low | $4.17 | $47.80 |
Enterprise Value | $228.22M | $82.99B |
Dividend Yield | — | 7.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
MPLX trades at $56.97, down 0.33% on the day, with a bullish technical signal supported by moving averages and key indicators like ADX. Financially, the company reported strong 2025 results with $11.47B revenue and $4.91B net income, though Q1 2026 EPS missed expectations. Analyst consensus is strongly positive with a $60.60 price target, and the recent $1.08 dividend underscores its income appeal.
The outlook for MPLX remains favorable, driven by its high-yield dividend, stable cash flows from fee-based contracts, and strategic focus on natural gas and NGL services. Key risks include exposure to energy commodity volatility and high debt levels. Upside potential hinges on execution of growth projects and sustained distribution growth amid a supportive midstream environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
